Coya Therapeutics (NASDAQ:COYA) is a clinical‐stage biotechnology company focused on the discovery and development of novel immunomodulatory therapies for autoimmune diseases. Founded in 2019 and headquartered in Cambridge, Massachusetts, the company leverages proprietary Fc-engineering technology to selectively activate regulatory T cells and restore immune tolerance. By harnessing the natural biology of immunoglobulin G (IgG) Fc domains, Coya aims to address underlying mechanisms of autoimmunity rather than merely treating symptoms.
The company’s lead candidate, CTH-347, is currently in Phase 1 clinical trials for rheumatoid arthritis, exploring its ability to modulate pathogenic immune responses and promote long-term disease control. Beyond rheumatoid arthritis, Coya maintains a diverse preclinical pipeline that targets autoimmune indications such as type 1 diabetes and multiple sclerosis. Its modular protein engineering platform allows rapid optimization of Fc-based biologics, offering scalability for a broad range of indications driven by dysregulated immunity.
Coya has established research and development operations in North America and Europe, collaborating with academic institutions and industry partners to advance its programs. In early 2022, the company completed a business combination and began trading on the Nasdaq under the ticker COYA, securing capital to accelerate its clinical development strategy and expand its therapeutic portfolio. Through strategic alliances and cross-border scientific exchanges, Coya seeks to position itself at the forefront of immune tolerance innovation.
The leadership team at Coya comprises seasoned biotechnology executives and scientists with extensive experience in immunology, drug development and regulatory affairs. Supported by a board of directors and an advisory panel of renowned immunologists, the company is guided by a commitment to translate cutting-edge science into novel therapies that improve the lives of patients with chronic autoimmune conditions. Coya’s mission is to redefine treatment paradigms by delivering safe, targeted therapies that address the root causes of autoimmunity.
